{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:05:35Z","timestamp":1792785935003,"version":"4.5.0"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30DK034987"],"award-info":[{"award-number":["P30DK034987"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P40OD010995"],"award-info":[{"award-number":["P40OD010995"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Crohn\u2019s and Colitis Foundation. S.G. received support from National Institutes of Health","award":["T32DK007737"],"award-info":[{"award-number":["T32DK007737"]}]},{"name":"Crohn\u2019s and Colitis Foundation. S.G. received support from National Institutes of Health","award":["P30DK034987"],"award-info":[{"award-number":["P30DK034987"]}]},{"name":"Crohn\u2019s and Colitis Foundation IBD Ventures","award":["1372889"],"award-info":[{"award-number":["1372889"]}],"id":[{"id":"https:\/\/ror.org\/05f2xbq60","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/100006370","name":"Small Business Innovation Research","doi-asserted-by":"publisher","award":["1R44DK145292-01"],"award-info":[{"award-number":["1R44DK145292-01"]}],"id":[{"id":"10.13039\/100006370","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Recent evidence has shown that ulcerative colitis patients with increased neutrophil biomarkers are linked to complicated disease and refractory response. In the pathology of colitis, neutrophils are recruited to the colon and yield acute damage via reactive oxygen species (ROS), degranulation, and neutrophil extracellular traps (NETosis). RAB27A is a regulator of intracellular membrane trafficking and has been shown to play a role in neutrophil activation by enabling the increased release of proteolytic granules and ROS. Studies have shown significant upregulation of RAB27A expression in biopsies of moderate and severe ulcerative colitis patients, while preclinical studies genetically deleting RAB27A in ulcerative colitis models have shown improved outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>To evaluate the impact of RAB27A inhibition in ulcerative colitis and lower activated neutrophil toxicity in the disease, we developed IMYX-3, a first-in-class small molecule oral inhibitor of RAB27A activity and applied it to the study of diseased neutrophils and models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>IMYX-3 lowers neutrophil ROS, degranulation, NETosis, and cytokine secretion. Preclinical efficacy was demonstrated in dextran sulfate sodium and Il10\u2212\/\u2212 mouse models, in which IMYX-3 treatment led to improved colon length, reduced systemic inflammation, lower levels of activated neutrophil function, and comparable disease outcomes compared with standard-of-care control mice. In vitro toxicity profiling as well as pharmacokinetic and toxicology studies in rodents and canines showed a favorable drug profile, with no significant adverse events observed at doses up to 30 times the predicted therapeutic range.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>IMYX-3 effectively inhibits RAB27A activation in neutrophils, yielding improved outcomes in preclinical disease models with no major safety concerns.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ibd\/izag170","type":"journal-article","created":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T11:52:00Z","timestamp":1785498720000},"page":"2004-2015","source":"Crossref","is-referenced-by-count":0,"title":["Modulating immune toxicity in ulcerative colitis using a small molecule RAB27A inhibitor"],"prefix":"10.1093","volume":"32","author":[{"given":"Meital","family":"Ben-David-Naim","sequence":"first","affiliation":[{"name":"Immunyx Pharma, JBP Minrav Building , Jerusalem, 91120,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Bijaoui","sequence":"additional","affiliation":[{"name":"Department of Developmental Biology and Cancer Research, Institute for Medical Research Israel Canada, Hebrew University Medical School , Jerusalem, 91120,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi","family":"Iluz","sequence":"additional","affiliation":[{"name":"Immunyx Pharma, JBP Minrav Building , Jerusalem, 91120,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Adams","sequence":"additional","affiliation":[{"name":"Immunyx Pharma, JBP Minrav Building , Jerusalem, 91120,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daryl C","family":"Drummond","sequence":"additional","affiliation":[{"name":"Immunyx Pharma, JBP Minrav Building , Jerusalem, 91120,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yatin","family":"Mankan","sequence":"additional","affiliation":[{"name":"Immunyx Pharma USA , New York, NY, 10013,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina H","family":"Eng","sequence":"additional","affiliation":[{"name":"Immunyx Pharma USA , New York, NY, 10013,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy W","family":"Herzog","sequence":"additional","affiliation":[{"name":"Center for Gastrointestinal Biology and Disease, Division of Gastroenterology and Hepatology, Department of Medicine, University of North Carolina , Chapel Hill, NC, 27599-7032,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Gray","sequence":"additional","affiliation":[{"name":"Center for Gastrointestinal Biology and Disease, Division of Gastroenterology and Hepatology, Department of Medicine, University of North Carolina , Chapel Hill, NC, 27599-7032,","place":["United States"]},{"name":"National Gnotobiotic Rodent Resource Center, University of North Carolina at Chapel Hill , Chapel Hill, NC,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan Balfour","family":"Sartor","sequence":"additional","affiliation":[{"name":"Center for Gastrointestinal Biology and Disease, Division of Gastroenterology and Hepatology, Department of Medicine, University of North Carolina , Chapel Hill, NC, 27599-7032,","place":["United States"]},{"name":"National Gnotobiotic Rodent Resource Center, University of North Carolina at Chapel Hill , Chapel Hill, NC,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zvi G","family":"Fridlender","sequence":"additional","affiliation":[{"name":"Hadassah-Hebrew University Medical Center Institute of Pulmonary Medicine, , Jerusalem, 91120,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6960-2419","authenticated-orcid":false,"given":"Seth J","family":"Salpeter","sequence":"additional","affiliation":[{"name":"Immunyx Pharma, JBP Minrav Building , Jerusalem, 91120,","place":["Israel"]},{"name":"Immunyx Pharma USA , New York, NY, 10013,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9692-5785","authenticated-orcid":false,"given":"Zvi","family":"Granot","sequence":"additional","affiliation":[{"name":"Immunyx Pharma, JBP Minrav Building , Jerusalem, 91120,","place":["Israel"]},{"name":"Department of Developmental Biology and Cancer Research, Institute for Medical Research Israel Canada, Hebrew University Medical School , Jerusalem, 91120,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,21]]},"reference":[{"key":"2026093014403006900_izag170-B1","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1016\/S2468-1253(22)00233-3","article-title":"ABX464 (obefazimod) for moderate-to-severe, active ulcerative colitis: a phase 2b, double-blind, randomised, placebo-controlled induction trial and 48 week, open-label extension","volume":"7","author":"Vermeire","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026093014403006900_izag170-B2","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.1016\/S0140-6736(22)00688-2","article-title":"Ustekinumab adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn\u2019s disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial","volume":"399","author":"Sands","year":"2022","journal-title":"Lancet"},{"key":"2026093014403006900_izag170-B3","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1111\/j.1440-1746.1997.tb00375.x","article-title":"Selective depletion of neutrophils by a monoclonal antibody, RP-3, suppresses dextran sulphate sodium-induced colitis in rats","volume":"12","author":"Natsui","year":"1997","journal-title":"J Gastroenterol Hepatol"},{"key":"2026093014403006900_izag170-B4","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.abb.2018.03.012","article-title":"Myeloperoxidase in the inflamed colon: a novel target for treating inflammatory bowel disease","volume":"645","author":"Chami","year":"2018","journal-title":"Arch Biochem Biophys"},{"key":"2026093014403006900_izag170-B5","doi-asserted-by":"publisher","first-page":"118","DOI":"10.3390\/jcm5120118","article-title":"The dual role of neutrophils in inflammatory bowel diseases","volume":"5","author":"W\u00e9ra","year":"2016","journal-title":"J Clin Med"},{"key":"2026093014403006900_izag170-B6","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/s41573-019-0054-z","article-title":"Neutrophils as emerging therapeutic targets","volume":"19","author":"N\u00e9meth","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"2026093014403006900_izag170-B7","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1093\/ibd\/izae032","article-title":"Comparison of fecal calprotectin and myeloperoxidase in predicting outcomes in inflammatory bowel disease","volume":"31","author":"Swaminathan","year":"2025","journal-title":"Inflamm Bowel Dis"},{"key":"2026093014403006900_izag170-B8","doi-asserted-by":"publisher","first-page":"908","DOI":"10.3748\/wjg.v27.i10.908","article-title":"Use of granulocyte\/monocytapheresis in ulcerative colitis: a practical review from a European perspective","volume":"27","author":"Dom\u00e8nech","year":"2021","journal-title":"World J Gastroenterol"},{"key":"2026093014403006900_izag170-B9","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1042\/BJ20050380","article-title":"The Rab27a-binding protein, JFC1, regulates androgen-dependent secretion of prostate-specific antigen and prostatic-specific acid phosphatase","volume":"391","author":"Johnson","year":"2005","journal-title":"Biochem J"},{"key":"2026093014403006900_izag170-B10","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1111\/j.1600-0854.2008.00838.x","article-title":"The Rab27a effectors JFC1\/Slp1 and Munc13-4 regulate exocytosis of neutrophil granules","volume":"9","author":"Brzezinska","year":"2008","journal-title":"Traffic"},{"key":"2026093014403006900_izag170-B11","doi-asserted-by":"publisher","first-page":"2950","DOI":"10.1128\/MCB.00417-13","article-title":"Upregulation of the Rab27a-dependent trafficking and secretory mechanisms improves lysosomal transport, alleviates endoplasmic reticulum stress, and reduces lysosome overload in cystinosis","volume":"33","author":"Johnson","year":"2013","journal-title":"Mol Cell Biol"},{"key":"2026093014403006900_izag170-B12","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1111\/jgh.13413","article-title":"Exosome in intestinal mucosal immunity","volume":"31","author":"Xu","year":"2016","journal-title":"J Gastroenterol Hepatol"},{"key":"2026093014403006900_izag170-B13","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1111\/cmi.12328","article-title":"The role of Rab27a in the regulation of neutrophil function","volume":"16","author":"Catz","year":"2014","journal-title":"Cell Microbiol"},{"key":"2026093014403006900_izag170-B14","doi-asserted-by":"publisher","first-page":"e12870","DOI":"10.1371\/journal.pone.0012870","article-title":"Distinct role of rab27a in granule movement at the plasma membrane and in the cytosol of NK cells","volume":"5","author":"Liu","year":"2010","journal-title":"PLoS One"},{"key":"2026093014403006900_izag170-B15","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1038\/ncb1552","article-title":"Rab27a regulates phagosomal pH and NADPH oxidase recruitment to dendritic cell phagosomes","volume":"9","author":"Jancic","year":"2007","journal-title":"Nat Cell Biol"},{"key":"2026093014403006900_izag170-B16","doi-asserted-by":"publisher","first-page":"11330","DOI":"10.1111\/jcmm.15726","article-title":"Rab27A promotes cellular apoptosis and ROS production by regulating the miRNA-124-3p\/STAT3\/RelA signalling pathway in ulcerative colitis","volume":"24","author":"Luo","year":"2020","journal-title":"J Cell Mol Med"},{"key":"2026093014403006900_izag170-B17","doi-asserted-by":"publisher","first-page":"25965","DOI":"10.1074\/jbc.M116.741884","article-title":"Identification of neutrophil exocytosis inhibitors (Nexinhibs), small molecule inhibitors of neutrophil exocytosis and inflammation: druggability of the small GTPase Rab27a","volume":"291","author":"Johnson","year":"2016","journal-title":"J Biol Chem"},{"key":"2026093014403006900_izag170-B18","doi-asserted-by":"publisher","first-page":"2851","DOI":"10.1021\/acs.jmedchem.8b00147","article-title":"Nitro-group-containing drugs","volume":"62","author":"Nepali","year":"2019","journal-title":"J Med Chem"},{"key":"2026093014403006900_izag170-B19","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1186\/s40168-024-01857-2","article-title":"Mouse adaptation of human inflammatory bowel diseases microbiota enhances colonization efficiency and alters microbiome aggressiveness depending on the recipient colonic inflammatory environment","volume":"12","author":"Gray","year":"2024","journal-title":"Microbiome"},{"key":"2026093014403006900_izag170-B20","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1172\/JCI118878","article-title":"Normal luminal bacteria, especially Bacteroides species, mediate chronic colitis, gastritis, and arthritis in HLA-B27\/human beta2 microglobulin transgenic rats","volume":"98","author":"Rath","year":"1996","journal-title":"J Clin Invest"},{"key":"2026093014403006900_izag170-B21","doi-asserted-by":"publisher","first-page":"1003871","DOI":"10.3389\/fimmu.2022.1003871","article-title":"Targeted nanoparticles modify neutrophil function","volume":"13","author":"V\u00f6ls","year":"2022","journal-title":"Front Immunol"},{"key":"2026093014403006900_izag170-B22","doi-asserted-by":"publisher","first-page":"e44328","DOI":"10.1371\/journal.pone.0044328","article-title":"Fecal lipocalin 2, a sensitive and broadly dynamic non-invasive biomarker for intestinal inflammation","volume":"7","author":"Chassaing","year":"2012","journal-title":"PLoS One"},{"key":"2026093014403006900_izag170-B23","doi-asserted-by":"publisher","first-page":"4860","DOI":"10.1038\/s41598-017-04071-3","article-title":"The Anti-Hiv candidate Abx464 dampens intestinal inflammation by triggering Il-22 production in activated macrophages","volume":"7","author":"Chebli","year":"2017","journal-title":"Sci Rep"},{"key":"2026093014403006900_izag170-B24","doi-asserted-by":"publisher","first-page":"S12","DOI":"10.1093\/ibd\/izae282.028","article-title":"Treatment of moderately to severely active ulcerative colitis with RO7790121 demonstrates early clinical response and symptom improvement \u2013 results from the phase 2B Tuscany-2 trial","volume":"31","author":"Allegretti","year":"2025","journal-title":"Inflamm Bowel Dis"},{"key":"2026093014403006900_izag170-B25","doi-asserted-by":"publisher","first-page":"1425251","DOI":"10.3389\/fimmu.2024.1425251","article-title":"The emerging role of neutrophil extracellular traps in ulcerative colitis","volume":"15","author":"Long","year":"2024","journal-title":"Front Immunol"},{"key":"2026093014403006900_izag170-B26","doi-asserted-by":"publisher","first-page":"1095098","DOI":"10.3389\/fimmu.2023.1095098","article-title":"Identifying neutrophil-associated subtypes in ulcerative colitis and confirming neutrophils promote colitis-associated colorectal cancer","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Immunol"},{"key":"2026093014403006900_izag170-B27","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1159\/000080079","article-title":"Adsorptive granulocyte and monocyte apheresis versus prednisolone in patients with corticosteroid-dependent moderately severe ulcerative colitis","volume":"70","author":"Hanai","year":"2004","journal-title":"Digestion"},{"key":"2026093014403006900_izag170-B28","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1053\/j.gastro.2008.04.023","article-title":"A randomized, double-blind, sham-controlled study of granulocyte\/monocyte apheresis for active ulcerative colitis","volume":"135","author":"Sands","year":"2008","journal-title":"Gastroenterology"},{"key":"2026093014403006900_izag170-B29","doi-asserted-by":"publisher","first-page":"612977","DOI":"10.3389\/fimmu.2020.612977","article-title":"Griscelli syndrome type 2 sine albinism: unraveling differential RAB27A effector engagement","volume":"11","author":"Ohishi","year":"2020","journal-title":"Front Immunol"},{"key":"2026093014403006900_izag170-B30","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s12931-023-02444-z","article-title":"Dipeptidyl peptidase-1 inhibition with brensocatib reduces the activity of all major neutrophil serine proteases in patients with bronchiectasis: results from the WILLOW trial","volume":"24","author":"Cipolla","year":"2023","journal-title":"Respir Res"},{"key":"2026093014403006900_izag170-B31","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1038\/s41423-021-00832-3","article-title":"Neutrophils in chronic inflammatory diseases","volume":"19","author":"Herrero-Cervera","year":"2022","journal-title":"Cell Mol Immunol"},{"key":"2026093014403006900_izag170-B32","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1007\/s00011-022-01627-6","article-title":"Neutrophils as emerging protagonists and targets in chronic inflammatory diseases","volume":"71","author":"Rawat","year":"2022","journal-title":"Inflamm Res"}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/32\/10\/2004\/70754930\/izag170.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/32\/10\/2004\/70754930\/izag170.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T18:40:38Z","timestamp":1790793638000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article\/32\/10\/2004\/8767738"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,21]]},"references-count":32,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,8,21]]},"published-print":{"date-parts":[[2026,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ibd\/izag170","relation":{},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"value":"1078-0998","type":"print"},{"value":"1536-4844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10]]},"published":{"date-parts":[[2026,8,21]]}}}